Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Jaakko Tuomilehto,
Prof. Gang Hu
Patients with asymptomatic hyperglycaemia (including impaired glucose tolerance) are at high risk for the development of a cardiovascular disease.
The fact that individuals with overt diabetes have increased risks for cardiovascular diseases (CVD) has long been confirmed, but the fact that patients with asymptomatic diabetes are also at high risk for the development of CVD has only been recognised recently. The issue of whether asymptomatic hyperglycaemia is a risk factor for CVD and whether the risk is graded has been debated for at least two decades. Recently, a new surge of interest in the relationship between asymptomatic hyperglycaemia and CVD risk has developed following the recent revision of diagnostic criteria for diabetes and milder degrees of hyperglycaemia in 1997 (1-2).
The most convincing evidence of increased CVD risk related to asymptomatic hyperglycaemia was provided by the DECODE (Diabetes Epidemiology: collaborative analysis Of Diagnostic criteria in Europe) study. In this study, data from 10 prospective European cohort studies including 15388 men and 7126 women aged 30-89 years were collaboratively analysed (3-4). Multivariate Cox proportional hazard analyses showed that the risk for death from all-cause, CVD, coronary heart disease (CHD) and stroke increased significantly in subjects with asymptomatic diabetes defined according to either the fasting plasma glucose 7.0 mmol/l or to the 2-hour post-load plasma glucose ≥11.1 mmol/l. People with impaired glucose tolerance (IGT) also had high risk of death compared with those without IGT, but subjects with impaired fasting glucose (IFG) did not have increased risk of death compared with those with normal fasting glucose levels (3-4). Furthermore, the DECODE study revealed that abnormalities in 2-hour glucose were better predictors of mortality from all cause, CVD and CHD than fasting glucose alone (3-4). A high 2-hour glucose concentration was found to be associated with an increased risk of death, independent of the level of fasting blood glucose, whereas mortality associated with the fasting glucose concentration depended on the level of 2-hour glucose (3).
More recently, we extended the observations of the DECODE study on the predictive value of 2-hour glucose vs fasting glucose with regard to the prediction of the risk of serious incident CHD events (CHD death and non-fatal myocardial infarction) based on five Finnish DECODE study cohorts (5). The data analysis indicated that in subjects without a prior history of diabetes the association of 2-hour glucose with CHD incidence is graded and independent, and that 2-hour glucose is superior to fasting glucose in assessing the risk of future CHD events. Thus, the DECODE study unequivocally confirmed that asymptomatic post-load hyperglycaemia independently increases cardiovascular morbidity and mortality and is a better predictor of the events than fasting hyperglycaemia. These findings are important especially in the elderly population because post-challenge glucose levels increase to a much greater extent with advancing age than fasting glucose. The need for similar assessment regarding mealtime versus fasting glucose and for evaluating the possible benefit of treatments focused on postprandial hyperglycaemia is required, especially in the elderly population.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97. 2. Report of a WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Geneva, World Health Organization, 1999. 3. DECODE Study group. Glucose tolerance and cardiovascular mortality: Comparison of the fasting and the 2-hour diagnostic criteria. Arch of Intern Med 2001; 161: 397-404. 4. DECODE Study Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21. 5. Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R, Tuomilehto J. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23: 1267-75.
Prof G. Hu, and Prof. J. Tuomilehto Helsinki, Finland Member and Chairman of the ESC Working Group on Epidemiology and Prevention
© 2017 European Society of Cardiology. All rights reserved